Zetagen Therapeutics' ZetaFuse has potential to treat degenerative disc disease in patients with late-stage cancer, according to a case study in the Journal of the American Academy of Orthopaedic Surgeons.
The case study focused on a Stage 4 lung cancer patient who has multilevel cervical degenerative disc disease, according to a Sept. 25 news release. ZetaFuse, a biologic used to promote bone formation in the patient's anterior cervical discectomy and fusion, "exceeded expectations" in the final results of the study.
The patient had a successful fusion eight months after surgery.
"Knowing the patient had been treated previously for his lung cancer with cytotoxic therapy and immunotherapy, which are known to negatively impact bone healing and, in spite of extensive exposure to these agents over the last three years, our patient showed an excellent bone healing response to the novel, drug eluting biomaterial of the ZetaFuse," Pedro Sanz-Altamira, MD, PhD, who had treated the case study patient for several years, said in the release.
Read the full publication here.